Transitioning patients with immune thrombocytopenia to second‐line therapy: Challenges and best practices-Reference-Cited by-同舟云学术

Transitioning patients with immune thrombocytopenia to second‐line therapy: Challenges and best practices

Published:2018-04-15 Issue:6 Volume:93 Page:816-823
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Cuker Adam¹^ORCID

Affiliation:

1. Department of Medicine and Department of Pathology & Laboratory Medicine, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphia Pennsylvania

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25092

Reference66 articles.

1. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

2. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura

3. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

4. How I treat refractory immune thrombocytopenia

5. Positioning new treatments in the management of immune thrombocytopenia

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fostamatinib for immune thrombocytopenic purpura in adult patients: A systematic review and meta‐analysis;eJHaem;2024-06-21

2. Epidemiology, Treatment Patterns, and Cost Analysis of Immune Thrombocytopenia in Spain between 2014 and 2020: A Population-based Study;TH Open;2024-05-31

3. Sustained response off‐treatment in eltrombopag‐treated adult patients with ITP who are refractory or relapsed after first‐line steroids: Primary, final, and ad‐hoc analyses of the Phase II TAPER trial;American Journal of Hematology;2023-11-28

4. Proteomic-Based Discovery of Predictive Biomarkers for Drug Therapy Response and Personalized Medicine in Chronic Immune Thrombocytopenia;BioMed Research International;2023-10-31

5. Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China;Research and Practice in Thrombosis and Haemostasis;2023-08